Stereoselective hepatic disposition of a diastereomeric pair of αvβ3 antagonists in rat

Xenobiotica

Volumn 33, Issue 11, 2003, Pages 1125-1137

  Prueksaritanont, T ^a   Xu, X ^a   Deluna, P ^a   Yamazaki, M ^a   Lin, J H ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 DINITROPHENOL; 3 [2 OXO 3 [3 (5,6,7,8 TETRAHYDRO 1,8 NAPHTHYRIDIN 2 YL)PROPYL]PYRROLIDIN 1 YL] 3 QUINOLIN 3 YLPROPANOIC ACID; ADENOSINE TRIPHOSPHATE; AMPHOLYTE; DRUG; GLUTATHIONE; GLYCOPROTEIN P; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 2; PROTEIN INHIBITOR; TRITIUM; UNCLASSIFIED DRUG; VERLUKAST;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BILE; BILIARY EXCRETION; CALCULATION; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DIASTEREOISOMER; DRUG ANTAGONISM; DRUG BILE LEVEL; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG TRANSPORT; DRUG UPTAKE; HYDROPHILICITY; HYPERBILIRUBINEMIA; INTRAHEPATIC BILE DUCT; ISOLATED LIVER; LIPOPHILICITY; LIVER; LIVER CLEARANCE; MALE; MEMBRANE VESICLE; NONHUMAN; RAT; RAT STRAIN; STEREOCHEMISTRY; XENOBIOTIC METABOLISM;

ANIMALS; AREA UNDER CURVE; BILE CANALICULI; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; HYPERBILIRUBINEMIA; INTEGRIN ALPHAVBETA3; LIVER; MALE; PERFUSION; PROPIONATES; PROPIONIC ACIDS; QUINOLINES; RATS; RATS, SPRAGUE-DAWLEY; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP;

ANIMALIA;

EID: 0345491347     PISSN: 00498254     EISSN: None     Source Type: Journal    
DOI: 10.1080/00498250310001609174     Document Type: Article

References (23)

1. AKITA, H., SUZUKI, H. and SUGIYAMA, Y., 2001, Sinusoidal efflux of taurocholate is enhanced in Mrp2-deficient rat liver. Pharmaceutical Research, 18, 1119-1125.
2. AYRTON, A. and MORGAN, P., 2001, Role of transport proteins in drug absorption, distribution and excretion. Xenobiotica, 31, 469-497.
3. BRADFORD, M. M., 1976, A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Analytical Biochemistry, 72, 248-254.
4. FORD, J. M. and HAIT, W. H., 1990, Pharmacology of drugs that alter multidrug resistance in cancer. Pharmacological Reviews, 42, 155-199.
5. GEKELER, V., ISE, W., SANDERS, K. H., ULRICH, W.-R. and BECK, J., 1995, The leukotriene LTD4 receptor antagonist MK571 specifically modulates MRP associated multidrug resistance. Biochemical and Biophysical Research Communications, 208, 345-352.
6. HARTMAN, G. D. and DUGGAN, M. E., 2000, Alpha (v) beta (3) integrin antagonists as inhibitors of bone resorption. Expert Opinion on Investigational Drugs, 9, 1281-1291.
7. HIROHASHI, T., SUZUKI, H., ITO, K., OGAWA, K., KUME, K., SHIMIZU, T. and SUGIYAMA, Y., 1998, Hepatic expression of multidrug resistance-associated protein-like proteins maintained in Eisai hyperbilirubinemic rats. Molecular Pharmacology, 53, 1068-1075.
8. KOBAYASHI, K., SOGAME, Y., HARA, H. and HAYASHI, K., 1990, Mechanism of glutathione S-conjugate transport in canalicular and basolateral rat liver plasma membranes. Journal of Biological Chemistry, 265, 7737-7741.
9. KÖNIG, J., NIES, A. T., CUI, Y., LEIER, I. and KEPPLER, D., 1999a, Conjugate export pumps of the multidrug resistance protein (MRP) family: localization, substrate specificity, and MRP2-mediated drug resistance. Biochimica et Biophysica Acta, 1461, 377-394.
10. KÖNIG, J., ROST, Y., CUI, Y. and KEPPLER, D., 1999b, Characterization of the human multidrug resistance protein isoform MRP3 localized to the basolateral hepatocyte membrane. Journal of Biological Chemistry, 274, 15181-15185.
11. KULLAK-UBLICK, G. A., BEUERS, U. and PAUMGARTNER, G, 2000, Hepatobiliary transport. Journal of Hepatology, 32 (suppl. 1), 3-18.
12. LEIER, I., JEDLITSCHKY, G., BUCHHOLZ, U., CENTER, M., COLE, S. P. C., DEELEY, R. G. and KEPPLER, D., 1996, ATP-dependent glutathione disulfide transport mediated by the MRP gene-encoded conjugate export pump. Biochemical Journal, 314, 433-437.
13. LIN, J. H., CHIBA, M., CHEN, I.-W., NISHIME, J. A., DELUNA, F. A., YAMAZAKI, M. and LIN, Y. J., 1999, Effect of dexamethasone on the intestinal first-pass metabolism of indinavir in rats: Evidence of cytochrome P-450A and P-glycoprotein induction. Drug Metabolism and Disposition, 27, 1187-1193.
14. MEIER, P. J. and STIEGER, B., 2002, Bile salt transporters. Annual Review of Physiology, 64, 635-661.
15. MEIJER, D. K. F., SMIT, J. W. and MULLER, M., 1997, Hepatobiliary elimination of cationic drugs: the role of P-glycoprotein and other ATP-dependent transporters. Advanced Drug Delivery Reviews, 25, 159-200.
16. PAYEN, L., COURTOIS, A., CAMPION, J.-P., GULLOUZO, A. and FARDEL, O., 2000, Characterization and inhibition by a wide range of xenobiotics of organic anion excretion by primary human hepatocytes. Biochemical Pharmacology, 60, 1967-1975.
17. PRUEKSARITANONT, T., MENG, Y., MA, B., LEPPERT, P., HOCHMAN, J., TANG, C., PERKINS, J., ZRADA, M., MEISSNER, R., DUGGAN, M. E. and LIN, J. H., 2002, Differences in the absorption, metabolism and biliary excretion of a diastereomeric pair of avb3 antagonists in rats: Limited role of P-glycoprotein. Xenobiotica, 32, 207-220.
18. SCHINKEL, A. H., WAGENAAR, E., MOL, C. A., VAN DEEMTER, L. and BORST, P., 1996, P-glycoprotein in the blood brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. Journal of Clinical Investigation, 97, 2517-2524.
19. SCHINKEL, A. H., WAGENAAR, E., VAN DEEMTER, L., MOL, C. A. and BORST, P., 1995, Absence of the mdr1a P-glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin and cyclosporin A. Journal of Clinical Investigation, 96, 1698-1705.
20. SMIT, J. W., SCHINKEL, A. H., WEERT, B. and MEIJER, D. K. F., 1998, Hepatobiliary and intestinal clearance of amphiphilic cationic drugs in mice in which both mdr1a and mdr1b genes have been disrupted. British Journal of Pharmacology, 124, 416-424.
21. TAKENAKA, O., HORIE, T., SUZUKI, H., KOBAYASHI, K. and SUGIYAMA, Y., 1995, Kinetic analysis of hepatobiliary transport for conjugative metabolites in the perfused liver of mutant rats (EHBR) with hereditary conjugative hyperbilirubinemia. Pharmaceutical Research, 12, 1746-1755.
22. YAMAZAKI, M., AKIYAMA, S., NI'INUMA, K., NISHIGAKI, R. and SUGIYAMA, Y., 1997, Biliary excretion of pravastatin in rats: contribution of the excretion pathway mediated by canalicular multispecific organic anion transporter (cMOAT). Drug Metabolism and Disposition, 25, 1123-1129.
23. YAMAZAKI, M., KOBAYASHI, K. and SUGIYAMA, Y., 1996, Primary active transport of pravastatin across the liver canalicular membrane in normal and mutant Eisai hyperbilirubinemic rats. Biopharmaceutics and Drug Disposition, 17, 607-621.